These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 39334280)

  • 1. Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events.
    Li Y; Sun S; Wu H; Zhao L; Peng W
    BMC Pharmacol Toxicol; 2024 Sep; 25(1):71. PubMed ID: 39334280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
    Shu Y; Ding Y; Dai B; Zhang Q
    Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database.
    Yu M; Zhou L; Cao M; Ji C; Zheng Y
    Front Immunol; 2024; 15():1397692. PubMed ID: 39234238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A real‑world pharmacovigilance study of FDA adverse event reporting system events for daratumumab.
    Yun X; Zhou Y; Wu D; Liu Y; Wu Q
    Expert Opin Drug Saf; 2024 May; 23(5):581-591. PubMed ID: 38600747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-Marketing Safety Concerns with Upadacitinib: A Disproportionality Analysis of the FDA Adverse Event Reporting system.
    Wu XP; Lu XK; Wang ZT; Huang L; Cai RW; Yu HM; Li JY; Xiao J
    Expert Opin Drug Saf; 2023; 22(10):975-984. PubMed ID: 37310063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Real-World Study on Adverse Reactions of Belimumab Based on the FDA Adverse Event Reporting System Database.
    Hai L; Wu J; Xie Y
    Pharmacoepidemiol Drug Saf; 2024 Oct; 33(10):e70037. PubMed ID: 39420647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Real-World Pharmacovigilance Study of Ceftazidime/Avibactam: Data Mining of the Food and Drug Administration Adverse Event Reporting System Database.
    Yao H; Wang Y; Peng Y; Huang Z; Gan G; Wang Z
    J Clin Pharmacol; 2024 Jul; 64(7):820-827. PubMed ID: 38375685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Data mining and safety analysis of avatrombopag: a retrospective pharmacovigilance study based on the US food and drug administration's adverse event reporting system.
    Zhu H; Wu M
    Sci Rep; 2024 May; 14(1):11262. PubMed ID: 38760419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS).
    Shi X; Cheng Q; Zhao YZ; Zou SP; Sun MH
    Osteoporos Int; 2023 Dec; 34(12):2047-2058. PubMed ID: 37594595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A real-world disproportionality analysis of cyclosporine from the FDA Adverse Event Reporting System (FAERS) database.
    Cui S; Li L; Liu W; Zhao B; Zhong X
    Braz J Med Biol Res; 2024; 57():e13392. PubMed ID: 39082578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse Event Assessment of Upadacitinib: A Pharmacovigilance Study Based on the FAERS Database.
    Yuan J; Lu H; Zuo X; Yin L; Pu Y; Zhang J
    Pharmacoepidemiol Drug Saf; 2024 Oct; 33(10):e70030. PubMed ID: 39385705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system.
    Xiang DC; Chen W; Fu ZW; Wu XH; Gao P; Wu Y
    Expert Opin Drug Saf; 2023; 22(10):943-955. PubMed ID: 37294594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suspected adverse drug reactions of rivaroxaban reported in the United States food and drug administration adverse event reporting system database: a pharmacovigilance study.
    Wu J; Wu J; Tang B; Wang X; Wei F; Zhang Y; Li L; Li H; Wang B; Wu W; Hong X
    Front Pharmacol; 2024; 15():1399172. PubMed ID: 39309013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pharmacovigilance study of FDA adverse events for sugammadex.
    Mao X; Zhang R; Liang X; Liu F; Dai Y; Wang M; Huang H; Fu G
    J Clin Anesth; 2024 Oct; 97():111509. PubMed ID: 38880003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse Event Reporting System (FAERS) database: A real-world pharmacovigilance study.
    Chen M; Huang Y; Jiang S; Ke C
    Lung Cancer; 2024 Oct; 196():107966. PubMed ID: 39342769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System.
    Liu Y; Dong C; He X; Shu Y; Wu P; Zou J
    J Pharm Pharm Sci; 2022; 25():377-390. PubMed ID: 36608646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse events with pemigatinib in the real world: a pharmacovigilance study based on the FDA Adverse Event Reporting System.
    Zhao D; Long X; Wang J
    Expert Opin Drug Saf; 2024 May; 23(5):599-605. PubMed ID: 38553867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
    Yin Y; Shu Y; Zhu J; Li F; Li J
    Sci Rep; 2022 Nov; 12(1):19555. PubMed ID: 36380085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-marketing safety concerns with abrocitinib: a real-world pharmacovigilance analysis of the FDA adverse event reporting system.
    Zhu Z; Liu M; Zhang H; Zheng H; Li J
    Expert Opin Drug Saf; 2024 May; ():1-8. PubMed ID: 38743462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A real-world disproportionality analysis of ospemifene: data mining of the public version of FDA adverse event reporting system.
    Wen H; Lu C; Zhang M; Qi X
    Expert Opin Drug Saf; 2023; 22(11):1133-1142. PubMed ID: 37578751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.